Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

Quantumup Jan. 23 at 7:50 PM

RBC Capital⬆️the PT on $GHRS to $40 from $33, reiterated at Outperform and said, Raising Price Target to $40 Following Psychedelics Symposium and Reiterating Outperform $JNJ $HELP ATAI CYBN MNMD CMPS RBC Capital additionally said: Following our Psychedelics Symposium and discussions with mgmt., payers, and docs, we are increasingly optimistic on GHRS's long-term sales opportunity with GH001 and are raising our price target to $40 from $33 based on updated assumptions about drug pricing in-line with Spravato. With EoP2 meeting later this year and pivotal trials initiation on track for later this year, we believe that GHRS remains a high quality mid-stage story in the emerging psychedelics space.

0 · Reply

Sunny3999 Jan. 23 at 5:32 PM

$PMN fast track designation and DSMB approval ready to go $ABBV $CELG $JNJ $PFE

0 · Reply

The1Albatross Jan. 23 at 4:09 PM

$JNJ Tutes upgrade spree, tough to see it yet

0 · Reply

gargoyl Jan. 23 at 3:01 PM

$MRK $JNJ $IBB Watching BLRX BiolineRx on a consolidation off ramp to beast mode 🦍 ……,,,,🏃‍♀️

0 · Reply

TheVaberWolf Jan. 23 at 12:33 PM

$AVAV $JNJ $MA $GRRR w

0 · Reply

Suite510 Jan. 23 at 12:04 PM

$JNJ $KVUE $SPX 67,000 Talc plaintiffs with singular jury awards averaging 20M 🤣🙈💵

0 · Reply

TheZaberWolf Jan. 23 at 11:00 AM

$JNJ Stocks with tight supply are getting all the action right now. SNSE fits the setup perfectly, with just ~800K shares outstanding. For context, SMX squeezed over 10,000% with a much larger float. Recent signals on SNSE suggest a potential short squeeze could be brewing. Definitely one to keep on your watchlist,

0 · Reply

FlashRaiders Jan. 22 at 11:31 PM

$PFE $PSTV $MOVE.X $JNJ ~

0 · Reply

RunnerSignals Jan. 22 at 10:02 PM

Exclusive Upside Alert! $OVV $META $ANF $JNJ $CUBE see analyst upgrades fresh moves brewing! full subscriber-only breakdown reveals who's set to run https://stocksrunner.com/news/2026-01-22-short-term-stocks-with-analyst-upgrades

0 · Reply

briefingcom Jan. 22 at 4:34 PM

$ABT: Abbott Labs (-7.8%) is sliding after a Q4 revenue miss and soft Q1 guidance overshadowed strength in Medical Devices and Diabetes Care. With sentiment already cautious after $JNJ, is near-term visibility the market’s biggest concern? Get all the details here: https://www.briefing.com/story-stocks/archive/2026/1/22/abbott-labs-catches-a-cold-q4-revenue-miss-and-cautious-guidance-chill-the-stock-(abt)?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link #Earnings #revenue #guidance #Healthcare #Stocks

0 · Reply

Johnson & Johnson is doing 'great things for patients,' CFO says

Jan 21, 2026, 11:20 PM EST - 1 day ago

Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

Jan 21, 2026, 6:45 PM EST - 1 day ago

Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

Jan 21, 2026, 1:56 PM EST - 2 days ago

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

Jan 21, 2026, 12:15 PM EST - 2 days ago

Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates

Jan 21, 2026, 10:00 AM EST - 2 days ago

OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings

OKLO ULTA

Jan 21, 2026, 7:26 AM EST - 2 days ago

J&J expects to hit $100 billion in revenue next year after new strategy pays off

Jan 21, 2026, 6:23 AM EST - 2 days ago

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Jan 21, 2026, 6:20 AM EST - 2 days ago

J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales

Jan 21, 2026, 6:20 AM EST - 2 days ago

Johnson & Johnson reports Q4 and Full-Year 2025 results

Jan 21, 2026, 1:07 AM EST - 2 days ago

Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Jan 20, 2026, 8:37 AM EST - 3 days ago

How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings

Jan 19, 2026, 8:00 AM EST - 4 days ago

Is Johnson & Johnson A Dividend Stock, Or Something Else?

Jan 19, 2026, 5:08 AM EST - 4 days ago

Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)

$TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide$

Jan 14, 2026, 4:30 PM EST - 8 days ago

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

Jan 13, 2026, 8:00 AM EST - 10 days ago

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Jan 13, 2026, 2:40 AM EST - 10 days ago

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

DHR GOOG LIN MSFT ORCL

Jan 12, 2026, 6:32 PM EST - 10 days ago

Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court

Jan 12, 2026, 2:06 PM EST - 11 days ago

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 7:40 AM EST - 12 days ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

AMGN CVX HD KO MRK NKE PG

Jan 10, 2026, 10:00 AM EST - 13 days ago

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Jan 10, 2026, 9:52 AM EST - 13 days ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

AMGN CRM DIS HD HON KO MRK

Jan 9, 2026, 9:59 AM EST - 14 days ago

Cramer's Mad Dash: Johnson & Johnson

Jan 9, 2026, 5:10 AM EST - 14 days ago

Johnson & Johnson Strikes Deal With White House to Lower Drug Prices

Jan 8, 2026, 9:33 PM EST - 14 days ago

Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

Jan 8, 2026, 8:43 PM EST - 14 days ago

Johnson & Johnson reaches deal with US government to lower drug prices

Jan 8, 2026, 8:24 PM EST - 14 days ago

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Jan 7, 2026, 8:00 AM EST - 16 days ago

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

Jan 6, 2026, 8:03 AM EST - 17 days ago

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

$Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma$

Jan 6, 2026, 6:52 AM EST - 17 days ago

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

Jan 2, 2026, 5:06 PM EST - 20 days ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

AMGN CVX HD KO MRK NKE PG

Jan 2, 2026, 4:17 PM EST - 20 days ago

Dow Jones 2025 Scorecard: Caterpillar, Nvidia Help Index Hit All-Time Highs – Top 5 Winners & Losers

CAT NVDA GS IBM

Jan 2, 2026, 8:00 AM EST - 21 days ago

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

Dec 31, 2025, 8:47 AM EST - 23 days ago

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR

Dec 30, 2025, 1:31 PM EST - 24 days ago

The Big 3: JNJ, SNDK, TWLO

TWLO SNDK

Dec 30, 2025, 9:55 AM EST - 24 days ago

Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now

Dec 30, 2025, 5:05 AM EST - 24 days ago

More Upside For JNJ Stock In 2026?

Dec 29, 2025, 1:56 PM EST - 25 days ago

Dogs of the Dow Had a Strong Year as Dividends Paid Off

HD IBM NKE UNH

Dec 29, 2025, 8:00 AM EST - 25 days ago

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

Dec 28, 2025, 6:44 AM EST - 26 days ago

Best Dividend Kings: December 2025

ABBV ABM ABT ADM ADP AWR BDX

Dec 26, 2025, 8:13 AM EST - 4 weeks ago

Johnson & Johnson halts mid-stage trial of experimental eczema drug

Dec 23, 2025, 11:41 AM EST - 4 weeks ago

J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling

Dec 23, 2025, 12:34 AM EST - 4 weeks ago

J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award

Dec 22, 2025, 11:15 PM EST - 4 weeks ago

Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder

Dec 20, 2025, 3:55 AM EST - 4 weeks ago

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

Dec 19, 2025, 5:54 PM EST - 4 weeks ago

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

Dec 18, 2025, 8:00 AM EST - 5 weeks ago

Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

Dec 18, 2025, 2:09 AM EST - 5 weeks ago

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

Dec 17, 2025, 6:49 PM EST - 5 weeks ago

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

Dec 15, 2025, 6:22 PM EST - 5 weeks ago

Final Trade: JNJ, NVO, UBER, BMY

BMY NVO UBER

Quantumup Jan. 23 at 7:50 PM

0 · Reply

Sunny3999 Jan. 23 at 5:32 PM

$PMN fast track designation and DSMB approval ready to go $ABBV $CELG $JNJ $PFE

0 · Reply

The1Albatross Jan. 23 at 4:09 PM

$JNJ Tutes upgrade spree, tough to see it yet

0 · Reply

gargoyl Jan. 23 at 3:01 PM

$MRK $JNJ $IBB Watching BLRX BiolineRx on a consolidation off ramp to beast mode 🦍 ……,,,,🏃‍♀️

0 · Reply

TheVaberWolf Jan. 23 at 12:33 PM

$AVAV $JNJ $MA $GRRR w

0 · Reply

Suite510 Jan. 23 at 12:04 PM

$JNJ $KVUE $SPX 67,000 Talc plaintiffs with singular jury awards averaging 20M 🤣🙈💵

0 · Reply

TheZaberWolf Jan. 23 at 11:00 AM

0 · Reply

FlashRaiders Jan. 22 at 11:31 PM

$PFE $PSTV $MOVE.X $JNJ ~

0 · Reply

RunnerSignals Jan. 22 at 10:02 PM

0 · Reply

briefingcom Jan. 22 at 4:34 PM

0 · Reply

Deeznutsswapmeet Jan. 22 at 4:22 PM

$JNJ $KVUE My guy blocked me! Please make sure he is aware that whatever garbage he posted today is without question 100% wrong.

0 · Reply

Deeznutsswapmeet Jan. 22 at 4:18 PM

$JNJ Another fortune teller!! Great call on this post. You really nailed it.

0 · Reply

IN0V8 Jan. 22 at 3:41 PM

$JNJ BofA Global Research raises price objective to $221 from $220 Citigroup raises target price to $250 from $232 JP Morgan raises target price to $225 from $205 Leerink Partners raises target price to $232.00 from $201.00 Morgan Stanley raises target price to $200 from $197 Raymond James raises target price to $237 from $209 Scotiabank raises target price to $265 from $230 Stifel raises target price to $220 from $205 TD Cowen raises target price to $250 from $222

0 · Reply

SparkyReturns Jan. 22 at 3:39 PM

$PFE Here's an idea for biotech investors. Big Pharma should pay attention to this tiny company that is saving lives and creating value. Look at the incredible setup for Seastar (ICU). 8M MC, with a TAM in the Billions (read that again); 2M NET revenue this year expected; 90% margins; Ramping up a product which will potentially/likely become Standard of Care for a number of conditions involving hyper-inflammation and sepsis (AKI, Cardiorenal, burn victims, transplant patients); Saves lives of AKI patients and ELIMINATES dialysis dependency; Total addressable market anywhere from 2B-20B; Zero debt; Pivotal adult AKI study to be completed in 12-15 months, possibly sooner; Being used at Mayo Clinic, Cinci Childrens, CHOP (Philadelphia), many more; 6 Breakthrough Device Designations (most ever); Cash burn reducing due to ramped up pediatric sales for longer runway; So, 8M MC for a company that will be worth Billions in a few years. $JNJ $TAK $NVS $MRK

0 · Reply

brief1066 Jan. 22 at 2:10 PM

$JNJ nothing can make this go green and stay green

1 · Reply

Shorting_BTC_Since_2009 Jan. 22 at 2:10 PM

$IBRX just a tip. immunity BIO with 13 consecutive Green Day’s is on SSR today!!! $LLY $MRNA $SLS $JNJ

0 · Reply

Shorting_BTC_Since_2009 Jan. 22 at 2:07 PM

$IBRX will break 24,000 followers today.$SLS $LLY $JNJ $MRNA

1 · Reply

PickAlpha Jan. 22 at 2:06 PM

PickAlpha Morning Report | 2026-01-22 — 6 material moves and analysis • Goldman raises 2026 gold target 5 400 — $GLD, $GDX • Gold and silver spike on geopolitical tensions — $GLD, $SLV • JNJ beats Q4 and raises 2026 guidance — $JNJ, $XLV • Etc.. https://research.pickalpha.ai/p/pickalpha-morning-report-2026-01-a54

0 · Reply

PickAlpha Jan. 22 at 1:53 PM

PickAlpha Morning Report - Company News: 2026.01.22 News Analysis - 1/2: Johnson & Johnson posts strong Q4 2025 results, lifts 2026 sales and EPS outlook | View: A clear beat-and-raise quarter, mid-single-digit 2026 growth guidance, and visible oncology and MedTech catalysts… $JNJ $XLV $SPY

0 · Reply

NeLoWtF_ Jan. 22 at 1:39 PM

$SLS The calm before the STORM. ⚡️ Pre-market just gave us a massive clue: a quick test of resistance saw us hitting $4.91 on tiny 120k volume. The path to $5+ is wide open and the "ask" is thin. Shorts are absolutely trapped and they know it. 🩳🔥 We are staring at the most anticipated IDMC PR of 2026. This isn't just another biotech play; this is a strategic asset grab. With $4.7B+ in TAM and GPS data that destroys the competition, the Institutional hunger is real. 🏛️💰 The 23rd January anniversary is tomorrow. The stage is set for the biggest Big Pharma BID WAR of the decade. $JNJ $MRK $BMY... who’s going to blink first? 20k shares locked in. Strong hands only. We don't sell for peanuts, we wait for the life-changing buyout. 💎🙌 #SLS #IDMC #GPS #Buyout #ShortSqueeze #BioTech

4 · Reply

Suite510 Jan. 22 at 1:13 PM

$JNJ $KVUE $SPX Will implode by March lol 😂 has expected In a statement from the Alabama-based Beasley Allen Law Firm, attorney Andy Birchfield took issue with J&J's characterization of the decision, saying the company should "reconsider its horribly flawed strategy." “This is a major victory for 67,000 women poisoned by talc and harmed again by Johnson & Johnson's pathological need to obstruct, delay and lie.

0 · Reply

viggizags Jan. 22 at 12:16 PM

$BTC.X for seriously, you guys should have just bought $JNJ coin. Now thats some performance. Ha

0 · Reply

Market Cap	525.25B
Revenue (ttm)	88.82B
Net Income (ttm)	14.07B
EPS (ttm)	N/A
PE Ratio	21.02
Forward PE	19.04
Profit Margin	15.84%
Debt to Equity Ratio	0.50

Volume	3,604,268
Avg Vol	9,135,516
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	80%
Beta	0.34
Analysts	Strong Sell
Price Target	$212.88